Oak Ridge spinout Verana Health has completed a $100m round led by existing investor GV that will help it expand its clinical database platform into new areas.

Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.

Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.

Azafaros, a metabolic disorder drug developer leveraging Leiden University and Amsterdam UMC inventions, has secured $28m in series A capital.

Verana Health completed a $100m round led by existing investor GV that will help it expand its clinical database platform into new areas.

Vineeta Agarwala has been confirmed as one of the general partners running the firm's $750m Bio Fund III following nearly five years at corporate venturing unit GV.

Existing investor Gradient Ventures invested in a series B round that almost doubled the clinical research software provider's overall funding to $45m.

The biomedical commercialisation hub will invest $200,000 in four to six startups each year from University of Washington and other local centres of research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Legend Capital contributed to a round that will fund progress of JenaValve's transcatheter aortic valve replacement towards US regulatory approval.